Industry Group: Pharmaceuticals
Country: Japan
Identifier: TKS:4528
Industry Group
Pharmaceuticals 111 out of 847
Universe
Global Universe 6723 out of 13845
Notice: The information provided is for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. Usage as a credit rating or as a benchmark is not permitted. Unless otherwise explicitly agreed in writing, usage for products and services, index creation, derivative work, portfolio or fund management, or any other usage are not permitted. By way of exception, usage is permitted only to the rated company, limited to a single reference of its own information in annual reporting and sustainability website, mentioning Sustainalytics as a source.
| ESG RISK RATING | INDUSTRY RANK | |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 28.3 Med. | 121 out of 847 |
| Ono Pharmaceutical Co., Ltd. | 27.7 Med. | 111 out of 847 |
| CSPC Pharmaceutical Group Ltd. | 36.4 High | 446 out of 847 |
| Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. | 36.9 High | 467 out of 847 |
| Sun Pharmaceutical Industries Ltd. | 36.8 High | 463 out of 847 |
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company’s ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization’s sustainability goals.
The ESG Risk Ratings measure a company’s exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Ono Pharmaceutical Co., Ltd.'s Exposure is Medium
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company’s ESG programs, practices and policies.
Ono Pharmaceutical Co., Ltd.'s Management of ESG Material Risk is Average
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Highest Controversy level that has impacted Ono Pharmaceutical Co., Ltd.'s ESG Risk Rating in the last three years
Our controversies research identifies companies involved in incidents that may negatively impact stakeholders, the environment or the company's operations.
Controversies form an important component of the ESG Risk Ratings as they can act as signals that management initiatives were insufficient or ineffective.
With an ESG License, companies can leverage their ESG Risk Rating and data as a part of their capital raising activities, marketing and promotional programs and sustainability initiatives.
Banks and lenders can use our ESG Risk Ratings and data as a part of a broader analysis of their clients as well as for innovative product solutions such as sustainability linked loans.
The ESG Risk Ratings can help investors to identify, understand and manage ESG risks at the security and portfolio level with the aim of improving the long-term performance of their equity and fixed income securities.
